PERRYSBURG, Ohio, June 04, 2025 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (“O-I Glass” or “O-I”) today announced the Company will participate in Wells Fargo’s 2025 Industrials and Materials Conference on Wednesday, June 11, 2025. O-I Glass Chief Financial Officer John Haudrich will present at 1:30 p.m. CT (2:30 p.m. ET). A live webcast of the presentation will be available at O-I Glass, Inc. - 1722509. The replay will be available through the above link within 24 hours of the presentation and will be archived for ...

WOOSTER, Ohio, June 04, 2025 (GLOBE NEWSWIRE) -- Main Street Financial Services Corp. (OTCQX:MSWV) (the “Company”) today announced that the Board of Directors (the “Board”) has terminated the Company’s President and Chief Executive Officer, Jay R. VanSickle II, effective June 3, 2025. In accordance with Mr. VanSickle’s employment contract, he was terminated without cause and is no longer a member of the Board. The Board has appointed Mark R. Witmer, currently a director and Executive Chair of the Company, a ...

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website ...

BOULDER, Colo., June 04, 2025 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA) (“Gaia” and/or the “Company”), a conscious media and community company, will present and host one-on-one meetings with investors at the Sidoti June Virtual Investor Conference, taking place on June 11-12, 2025. Gaia’s presentation is scheduled for Thursday, June 12th. The Company’s CEO James Calhoun and CFO Ned Preston will also host virtual one-on-one meetings with investors on Wednesday and Thursday, June 11th and 12th. To registe ...

Complements and enhances sustainability and infrastructure expertiseTORONTO and WASHINGTON, D.C., June 04, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ, TSX: CIGI), a leading diversified professional services and investment management company, announced today that it has entered into a definitive agreement to acquire a controlling interest in Astris Infrastructure, LLC (“Astris Finance”), a global investment banking firm specializing in infrastructure and energy transition. Under Colliers’ unique partnership m ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ:CIFR) (“Cipher” or the “Company”) today released its unaudited production and operations update for May 2025. Key Highlights Key MetricsMay 2025BTC Mined1179BTC Sold64BTC Held2966Deployed Mining Rigs75,000Month End Operating Hashrate (EH/s)13.5Month End Fleet Efficiency (J/TH)18.9 1 Includes May power sales estimates (based on current meter dat ...

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one investor meetings ...

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus PlanTORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025, it presented new manufacturing process data at the 4th annual meeting of the Israeli Society for Extracellular Vesicles Research (“ISEVR”), a conference dedicated to cutting-edge exosome science. Additionally, the Company will seek sh ...

DELAWARE, Ohio, June 04, 2025 (GLOBE NEWSWIRE) -- Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced fiscal second quarter 2025 results. Fiscal Second Quarter 2025 Financial Highlights: (all results compared to the second quarter of 2024 unless otherwise noted) Net income increased 6.5% to $47.3 million or $0.82 per diluted Class A share compared to net income of $44.4 million or $0.77 per diluted Class A share. Net income, excluding the impact of ...

Core Insights - Cullinan Therapeutics has advanced its leadership in T cell engager (TCE) development for autoimmune diseases, with both a CD19 TCE and BCMA TCE in its pipeline [1] - The company has strengthened its portfolio of autoimmune programs, aiming to address a broader range of diseases while ensuring cash runway into 2028 [1][5] - Cullinan has entered into an agreement with Genrix Bio for an exclusive global license to velinotamig, a BCMAxCD3 bispecific T cell engager, which has shown promising efficacy in treating relapsed/refractory multiple myeloma [2][3] Company Developments - Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory multiple myeloma [2] - The agreement includes an upfront license fee of $20 million, with potential future payments of up to $292 million in development and regulatory milestones, plus up to $400 million in sales-based milestones [4] - Cullinan plans to leverage data from Genrix's Phase 1 study in China to accelerate global clinical development of velinotamig in autoimmune diseases [3][4] Industry Context - T cell engagers are viewed as the next wave of innovation in autoimmune diseases, with BCMA as a promising target for a precise and potentially disease-modifying approach [3] - The collaboration with Genrix Bio is expected to enhance Cullinan's capabilities in developing therapies for autoimmune diseases, addressing the needs of a wider patient population [4][10]